Department of Biochemistry, University of Cambridge, Cambridge, UK.
Br J Pharmacol. 2013 Jun;169(4):736-47. doi: 10.1111/bph.12166.
The 5-HT3B subunit was first cloned in 1999, and co-expression with the 5-HT3A subunit results in heteromeric 5-HT₃AB receptors that are functionally distinct from homomeric 5-HT₃A receptors. The affinities of competitive ligands at the two receptor subtypes are usually similar, but those of non-competitive antagonists that bind in the pore often differ. A competitive ligand and allosteric modulator that distinguishes 5-HT₃A from 5-HT₃AB receptors has recently been described, and the number of non-competitive antagonists identified with this ability has increased in recent years. In this review, we discuss the differences between 5-HT₃A and 5-HT₃AB receptors and describe the possible sites of action of compounds that can distinguish between them.
5-HT3B 亚基于 1999 年首次被克隆,与 5-HT3A 亚基共表达可产生功能上不同于同源 5-HT3A 受体的异源 5-HT3AB 受体。两种受体亚型的竞争性配体的亲和力通常相似,但结合在孔中的非竞争性拮抗剂的亲和力往往不同。最近描述了一种能够区分 5-HT3A 和 5-HT3AB 受体的竞争性配体和变构调节剂,近年来,具有这种能力的非竞争性拮抗剂的数量有所增加。在这篇综述中,我们讨论了 5-HT3A 和 5-HT3AB 受体之间的差异,并描述了能够区分它们的化合物的可能作用部位。